These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18465678)

  • 1. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
    Quintás-Cardama A; Cortes J
    IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homoharringtonine for the treatment of chronic myelogenous leukemia.
    Quintás-Cardama A; Cortes J
    Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Cancer; 2009 Dec; 115(23):5382-93. PubMed ID: 19739234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine and omacetaxine for myeloid hematological malignancies.
    Lü S; Wang J
    J Hematol Oncol; 2014 Jan; 7():2. PubMed ID: 24387717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.
    Nazha A; Kantarjian H; Cortes J; Quintás-Cardama A
    Expert Opin Pharmacother; 2013 Oct; 14(14):1977-86. PubMed ID: 23875628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omacetaxine mepesuccinate in chronic myeloid leukemia.
    Al Ustwani O; Griffiths EA; Wang ES; Wetzler M
    Expert Opin Pharmacother; 2014 Nov; 15(16):2397-405. PubMed ID: 25301179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
    Chung C
    Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omacetaxine mepesuccinate for the treatment of leukemia.
    Kim TD; Frick M; le Coutre P
    Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
    Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
    Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
    Wang Q; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
    Narayanan V; Gutman JA; Pollyea DA; Jimeno A
    Drugs Today (Barc); 2013 Jul; 49(7):447-56. PubMed ID: 23914353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
    Damlaj M; Lipton JH; Assouline SE
    Expert Opin Drug Saf; 2016 Sep; 15(9):1279-86. PubMed ID: 27367461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
    Cortes J; Digumarti R; Parikh PM; Wetzler M; Lipton JH; Hochhaus A; Craig AR; Benichou AC; Nicolini FE; Kantarjian HM;
    Am J Hematol; 2013 May; 88(5):350-4. PubMed ID: 23468307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate).
    Novotny L; Al-Tannak NF; Hunakova L
    Neoplasma; 2016; 63(4):495-503. PubMed ID: 27268912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.
    Alvandi F; Kwitkowski VE; Ko CW; Rothmann MD; Ricci S; Saber H; Ghosh D; Brown J; Pfeiler E; Chikhale E; Grillo J; Bullock J; Kane R; Kaminskas E; Farrell AT; Pazdur R
    Oncologist; 2014 Jan; 19(1):94-9. PubMed ID: 24309980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
    Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
    Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.
    Khoury HJ; Cortes J; Baccarani M; Wetzler M; Masszi T; Digumarti R; Craig A; Benichou AC; Akard L
    Leuk Lymphoma; 2015 Jan; 56(1):120-7. PubMed ID: 24650054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
    Klag T; Härtel N; Erben P; Schwaab J; Schnetzke U; Schenk T; Hochhaus A; La Rosée P
    Leukemia; 2012 Jun; 26(6):1321-8. PubMed ID: 22289991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
    Cortes JE; Nicolini FE; Wetzler M; Lipton JH; Akard L; Craig A; Nanda N; Benichou AC; Leonoudakis J; Khoury HJ; Hochhaus A; Baccarani M; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):584-91. PubMed ID: 23787123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omacetaxine as an anticancer therapeutic: what is old is new again.
    Wetzler M; Segal D
    Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.